0001628280-23-041392.txt : 20231213 0001628280-23-041392.hdr.sgml : 20231213 20231213074245 ACCESSION NUMBER: 0001628280-23-041392 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231213 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIFAST INC CENTRAL INDEX KEY: 0000910329 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090] IRS NUMBER: 133714405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31573 FILM NUMBER: 231482979 BUSINESS ADDRESS: STREET 1: 11445 CRONHILL DRIVE CITY: OWINGS MILLS STATE: MD ZIP: 21117 BUSINESS PHONE: 7327640619 MAIL ADDRESS: STREET 1: 11445 CRONHILL DRIVE CITY: OWINGS MILLS STATE: MD ZIP: 21117 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHRITE INC DATE OF NAME CHANGE: 19951120 FORMER COMPANY: FORMER CONFORMED NAME: XX DATE OF NAME CHANGE: 19950619 FORMER COMPANY: FORMER CONFORMED NAME: 00 DATE OF NAME CHANGE: 19950619 8-K 1 med-20231213.htm 8-K med-20231213
0000910329FALSE00009103292023-12-132023-12-130000910329exch:XNYS2023-12-132023-12-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 13, 2023
MEDIFAST, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other
jurisdiction of incorporation)
001-31573
(Commission
File Number)
13-3714405
(I.R.S. Employer
Identification No.)
100 International Drive, Baltimore, Maryland 21202
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (410) 581-8042
N/A
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.001 per share
MED
New York Stock Exchange
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o



Item 8.01.    Other Events.

On December 13, 2023, Medifast, Inc. (the "Company") issued a press release announcing (i) that it, through and certain of its wholly owned subsidiaries entered into a collaboration agreement with LifeMD, Inc. (Nasdaq: LFMD) and (ii) an adjustment to the Company's capital allocation policy.

The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Item 9.01.    Financial Statements and Exhibits.


Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MEDIFAST, INC.
By:/s/ James P. Maloney
James P. Maloney
Chief Financial Officer
Dated: December 13, 2023

 EX-99.1 2 pressrelease12132023.htm EX-99.1 Document

Medifast Initiates Business Transformation by Entering the Medically Supported Weight Loss Market through Collaboration with LifeMD, a Virtual Primary Care Provider, and Adjusting its Capital Allocation Policy

Health and wellness company makes $20 million capital commitment to LifeMD, enters medically supported weight loss market projected to reach up to $100 billion by 2030

Company discontinues quarterly cash dividend and intends to invest in initiatives aimed at driving customer acquisition and customer experience to reignite growth

Conference call to discuss Medifast and LifeMD collaboration begins at 10 AM EST today

BALTIMORE, Dec. 13, 2023 -- Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today launched the first phase of its business transformation, as part of its commitment to providing comprehensive health and wellness solutions to customers across the United States. The company will expand into the medically supported weight loss market through a collaboration with LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care. This collaboration brings together OPTAVIA’s personalized habit-based, coach-guided approach with medical expertise from board-certified affiliated LifeMD clinicians and access to weight loss medications, including GLP-1s. This establishes Medifast’s entrance into the medically supported weight loss market, which is expected to reach up to $100 billion by 2030.*

"This is a pivotal moment in our business as we begin an aggressive transformation, committing more resources than ever before to our OPTAVIA brand and driving growth in this evolving health and wellness landscape,” said Dan Chard, Chairman and CEO of Medifast. “Millions of people are seeking a solution that I believe we are uniquely positioned to provide. Together, Medifast and LifeMD expect to deliver a comprehensive approach to health starting with weight management, built around a powerful model of support that includes an independent OPTAVIA Coach and a board-certified affiliated clinician. As a physician-founded company with a long-standing scientific and clinical heritage, we remain committed to helping even more people make living a healthy lifestyle second nature.”

Strategic Collaboration with LifeMD

Medifast has committed to make a $20 million investment in LifeMD, including an expected $10 million in contributions to support the collaboration, funding enhancements to LifeMD’s platform, operations and supporting infrastructure along with the purchase of $10 million of LifeMD’s common stock. In connection with Medifast’s investment, LifeMD has agreed to customary demand and piggyback registration rights which may expire no later than five years from December 11, 2023, and granted Medifast board observer rights, allowing for participation, without voting rights, in LifeMD’s Board meetings. The collaboration between Medifast and LifeMD is intended to create a comprehensive health solution to combat the escalating obesity crisis, including addressing the growing demand for medically supported weight loss by integrating clinician care with one-on-one OPTAVIA Coach support, community support, clinically proven plans and scientifically developed products, and a proprietary Habits of Health® Transformational System.

Medifast selected LifeMD as its partner following a successful pilot program focused on providing personalized care to support holistic health rather than weight loss alone. Independent research commissioned by Medifast revealed that most individuals interested in weight loss medications are looking for support beyond prescriptions, including clarity on how to incorporate components of healthy living, such as proper nutrition and exercise, into their lifestyles while utilizing these medical solutions. LifeMD brings a robust and scalable technology platform, which allows for a highly tailored and streamlined coach and clinician-driven model, and has invested in building a clinical team anchored by


full-time employed clinicians licensed to practice in all 50 states. This patient-centric care model creates significant opportunity for future collaborations that result in better support for individuals looking to reach their health goals at any point within their journeys.

“A shared philosophy of prioritizing holistic care and focus on lifelong health makes this a natural collaboration between our two companies,” said Justin Schreiber, Chairman and CEO of LifeMD. “Medifast’s investment in LifeMD is affirmation of our differentiated virtual care platform and clinical care model that provides tremendous value for our partners, addressing the unique health goals of our combined customer bases across multiple healthcare sectors and conditions. LifeMD is pleased to partner with Medifast to deliver a new model that has the ability to significantly transform the weight management industry.”

This month, Medifast launched two new product bundles designed specifically for those utilizing medically supported weight loss: “OPTAVIA Nutrition Kit for Medically Supported Weight Loss” and “OPTAVIA Muscle Health Kit for Medically Supported Weight Loss”. Evidence suggests that the loss of lean body mass can range from 20-50% of total weight loss for those on medically supported weight loss medications.** With the inclusion of these product bundles, OPTAVIA provides the tools to make healthy eating – and a healthy lifestyle – second nature, both at the start of a medical weight loss journey and while transitioning off medication.

Investment in Growth and Capital Allocation

The company has updated its capital allocation priorities following a thorough review. Medifast’s Board of Directors has elected to discontinue the company’s quarterly cash dividend, effective immediately. The Board of Directors believes that discontinuing the dividend at this time is in the best interest of the company and its stockholders, as it allows the company to redirect capital to invest in technology and growth initiatives. This is intended to improve customer acquisition and customer experience, which the company expects will generate higher long-term stockholder returns, as well as allow for stock repurchases when management and the Board deem it appropriate. The investments include a new marketing campaign designed to increase brand awareness and drive customer adoption.

“The LifeMD collaboration is just one of several major growth initiatives we plan to capitalize on in the years ahead, and we believe investing in our business will deliver the most compelling long-term return for our stockholders. Discontinuing the dividend provides the flexibility needed to continue evolving our model as we enter an exciting new chapter for our independent OPTAVIA Coaches, customers, employees and stockholders,” added Chard.

Conference Call Information

A conference call to discuss the collaboration is scheduled for today, Wednesday, December 13, 2023, at 10:00 AM EST. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast’s website at www.MedifastInc.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1647146&tp_key=8c4bcb15e1 and will be archived online and available through March 13, 2024. In addition, listeners may dial (877) 451-6152 to join via telephone. A telephonic playback will be available from 2:00 PM EST, December 13, 2023, through December 20, 2023. Participants can dial (844) 512-2921 and enter access code 13743024 to hear the playback. Slides describing the announcement are available at https://ir.medifastinc.com/events.


About Medifast
Medifast (NYSE: MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, which provides people with a simple, yet comprehensive approach to help


them achieve lasting optimal health and wellbeing. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent Coaches and Community support. As a physician-founded company with a 40+ year history, Medifast is a leader in the U.S. weight management industry. Through a collaboration with the national virtual primary care provider LifeMD, OPTAVIA customers have access to board-certified affiliated clinicians and medications, such as GLP-1s, that support treatment plans for obesity and other health conditions. The company continues to innovate and build upon its scientific and clinical heritage to fulfill its mission of offering the world Lifelong Transformation, One Healthy Habit at a Time®. Medifast was recognized in 2023 by Financial Times as one of The Americas' Fastest Growing Companies and in 2022 as one of America's Best Mid-Sized Companies by Forbes. For more information, visit MedifastInc.com and OPTAVIA.com and follow @Medifast on X.

For further information: Public Relations: Jessica Oring, Jessica.Oring@medifastinc.com; Investor Relations: Steven Zenker, Steven.Zenker@medifastinc.com

Forward Looking Statements
Please Note: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "expect," “believe,” “anticipate,” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors, including, among others: risks associated with Medifast's direct-to-consumer business model; the success of collaborations entered into to bring Medifast’s products to additional customer demographics; planned investments; disruptions in Medifast's supply chain; Medifast's inability to continue to develop new products; effectiveness of Medifast's advertising and marketing programs, including use of social media by independent OPTAVIA Coaches; Medifast's inability to maintain and grow the network of independent OPTAVIA Coaches; the departure of one or more key personnel; Medifast's inability to protect against product liability claims; Medifast's planned growth into domestic and international markets; adverse publicity associated with Medifast's products; fluctuations of Medifast's common stock market price; the prolonged effects of COVID-19 on consumer spending and disruptions to Medifast's distribution network, supply chains and operations; increases in competition or litigation; and the consequences of other geopolitical events, including natural disasters, global health crises, acts of war, climate change, regulatory changes, increases in costs of raw materials, fuel, or other energy, transportation, or utility costs and in the costs of labor and employment, labor shortages, supply chain issues and the resulting impact on market conditions and consumer sentiment and spending. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

*Terence Flynn, Framing the Mounjaro bull case in diabesity, Morgan Stanley Research, 9/14/23

**Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab. 2019;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247.

 EX-101.SCH 3 med-20231213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 med-20231213_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 med-20231213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Exchange [Domain] Exchange [Domain] Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Entity Address, City or Town Entity Address, City or Town Written Communications Written Communications Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 med-20231213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 13, 2023
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Dec. 13, 2023
Entity Registrant Name MEDIFAST, INC.
Entity Address, Address Line One 100 International Drive
Entity Address, City or Town Baltimore
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21202
City Area Code 410
Local Phone Number 581-8042
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol MED
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000910329
Amendment Flag false
Entity Tax Identification Number 13-3714405
Entity File Number 001-31573
Entity Incorporation, State or Country Code DE
NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Security Exchange Name NYSE
XML 8 med-20231213_htm.xml IDEA: XBRL DOCUMENT 0000910329 2023-12-13 2023-12-13 0000910329 exch:XNYS 2023-12-13 2023-12-13 0000910329 false 8-K 2023-12-13 MEDIFAST, INC. DE 001-31573 13-3714405 100 International Drive Baltimore MD 21202 410 581-8042 Common Stock, par value $0.001 per share MED NYSE false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 2 22 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.medifast1.com/role/Cover Cover Cover 1 false false All Reports Book All Reports med-20231213.htm med-20231213.xsd med-20231213_def.xml med-20231213_lab.xml med-20231213_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "med-20231213.htm": { "nsprefix": "med", "nsuri": "http://www.medifast1.com/20231213", "dts": { "inline": { "local": [ "med-20231213.htm" ] }, "schema": { "local": [ "med-20231213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd" ] }, "definitionLink": { "local": [ "med-20231213_def.xml" ] }, "labelLink": { "local": [ "med-20231213_lab.xml" ] }, "presentationLink": { "local": [ "med-20231213_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 28, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.medifast1.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20231213.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20231213.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2023", "localname": "XNYS", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExchangeDomain", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001628280-23-041392-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-041392-xbrl.zip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